|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online 3 January 2006
doi: 10.1242/jcs.02741
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research Article |
Tumor Immunology Programme, D010, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
* Author for correspondence (e-mail: P.Altevogt{at}dkfz.de)
Accepted 17 October 2005
CD24 is a small, heavily glycosylated cell-surface protein which is linked to the membrane via a glycosyl-phosphatidylinositol (GPI-) anchor and therefore localizes in lipid rafts. CD24 is widely used as a cell-lineage marker for hematopoietic cells. CD24 is also expressed on a variety of human carcinomas, including epithelial ovarian, breast, prostate, colon and lung cancer and has been linked to poor prognosis. Except for its role as a ligand for P-selectin on carcinoma and myeloid cells, a specific function for CD24 has not been determined. Here we show that CD24 affects the function of the chemokine receptor CXCR4. Using isolated CD19-positive bone marrow B cells from CD24-knockout mice and CD24–/– pre-B lymphocytic cell lines, we demonstrate that CD24 expression reduces SDF-1-mediated cell migration and signalling via CXCR4. We observed that the loss of CD24 augmented cellular cholesterol levels and enhanced CXCR4 lipid raft association. Altered chemotactic migration and raft residence was also observed in MDA-MB-231 breast cancer cells expressing high and low levels of CD24 and CXCR4 receptor. MDA-MB-231 cells expressing low levels of CD24 also showed enhanced tumour formation in NOD/SCID mice compared with cells overexpressing CD24. These results demonstrate a novel role for CD24 as a regulator of CXCR4 function that could be relevant for breast cancer growth and metastasis.
Key words: CD24, Cholesterol, CXCR4, SDF-1
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. Sameermahmood, M. Balasubramanyam, T. Saravanan, and M. Rema Curcumin Modulates SDF-1{alpha}/CXCR4-Induced Migration of Human Retinal Endothelial Cells (HRECs) Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3305 - 3311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sagiv, A. Starr, U. Rozovski, R. Khosravi, P. Altevogt, T. Wang, and N. Arber Targeting CD24 for Treatment of Colorectal and Pancreatic Cancer by Monoclonal Antibodies or Small Interfering RNA Cancer Res., April 15, 2008; 68(8): 2803 - 2812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Siddiqui, K. A. Harvey, G. P. Zaloga, and W. Stillwell Modulation of Lipid Rafts by {Omega}-3 Fatty Acids in Inflammation and Cancer: Implications for Use of Lipids During Nutrition Support Nutr Clin Pract, February 1, 2007; 22(1): 74 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Fogel, S. S. Young, D. M. Hawkins, and N. Ledirac Inferential, robust non-negative matrix factorization analysis of microarray data Bioinformatics, January 1, 2007; 23(1): 44 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zeng, I. J. Samudio, M. Munsell, J. An, Z. Huang, E. Estey, M. Andreeff, and M. Konopleva Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias Mol. Cancer Ther., December 1, 2006; 5(12): 3113 - 3121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Wicha Cancer stem cells and metastasis: lethal seeds. Clin. Cancer Res., October 1, 2006; 12(19): 5606 - 5607. [Full Text] [PDF]
|
|
|
|
|
|
M. Balic, H. Lin, L. Young, D. Hawes, A. Giuliano, G. McNamara, R. H. Datar, and R. J. Cote Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res., October 1, 2006; 12(19): 5615 - 5621. [Abstract] [Full Text] [PDF]
|
|
